{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:40:47Z","timestamp":1791906047933,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejpb.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T11:32:11Z","timestamp":1562931131000},"page":"435-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices"],"prefix":"10.1016","volume":"142","author":[{"given":"Xavier J.H.","family":"Pepin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan P.","family":"Plumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean S.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile M.","family":"Krejsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilee A.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Ingallinera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Greg","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpb.2019.07.011_b0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11095-012-0861-y","article-title":"Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices","volume":"30","author":"Mirza","year":"2013","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2019.07.011_b0010","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1208\/s12248-016-9966-2","article-title":"Regulatory experience with in vivo in vitro correlations (IVIVC) in new drug applications","volume":"18","author":"Suarez-Sharp","year":"2016","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.ejpb.2019.07.011_b0015","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-018-0213-x","article-title":"Dissolution and translational modeling strategies enabling patient-centric drug product development: the M-CERSI workshop summary report","volume":"20","author":"Abend","year":"2018","journal-title":"AAPS J."},{"issue":"1\u20133","key":"10.1016\/j.ejpb.2019.07.011_b0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0168-3659(01)00268-1","article-title":"Regulatory perspectives on in vitro (dissolution)\/in vivo (bioavailability) correlations","volume":"72","author":"Uppoor","year":"2001","journal-title":"J. Control. Rel.: Offic. J. Control. Rel. Soc."},{"key":"10.1016\/j.ejpb.2019.07.011_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2017.02.029","article-title":"A survey on IVIVC\/IVIVR development in the pharmaceutical industry - past experience and current perspectives","volume":"102","author":"Nguyen","year":"2017","journal-title":"Euro. J. Pharm. Sci.: Offic. J. Euro. Feder. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2019.07.011_b0030","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s11095-008-9642-z","article-title":"Dynamic dissolution testing to establish in vitro\/in vivo correlations for montelukast sodium, a poorly soluble drug","volume":"25","author":"Okumu","year":"2008","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1208\/s12248-008-9034-7","article-title":"Clinical relevance of dissolution testing in quality by design","volume":"10","author":"Dickinson","year":"2008","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.ejpb.2019.07.011_b0040","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/acs.molpharmaceut.6b00497","article-title":"Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets","volume":"13","author":"Pepin","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.07.011_b0045","unstructured":"Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development. in M-CERSI. 2017. Baltimore."},{"key":"10.1016\/j.ejpb.2019.07.011_b0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejps.2017.03.011","article-title":"Mechanistic investigation of the negative food effect of modified release zolpidem","volume":"102","author":"Andreas","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.xphs.2016.10.008","article-title":"Assessment of bioequivalence of weak base formulations under various dosing conditions using physiologically based pharmacokinetic simulations in virtual populations. Case examples: ketoconazole and posaconazole","volume":"106","author":"Cristofoletti","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jps.24603","article-title":"Characterization of human duodenal fluids in fasted and fed state conditions","volume":"105","author":"Riethorst","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2019.07.011_b0065","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1572-0241.2003.07586.x","article-title":"Influence of age and gender on gastric acid secretion as estimated by integrated acidity in patients referred for 24-hour ambulatory pH monitoring","volume":"98","author":"Shih","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.ejpb.2019.07.011_b0070","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1046\/j.1365-2036.2001.01011.x","article-title":"Ambulatory gastric pH monitoring: proper probe placement and normal values","volume":"15","author":"Fackler","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejpb.2019.07.011_b0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gut.36.4.539","article-title":"Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole","volume":"36","author":"Verd\u00fa","year":"1995","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.ejpb.2019.07.011_b0080","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1015922903843","article-title":"Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations","volume":"5","author":"Mojaverian","year":"1988","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2019.07.011_b0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1248\/bpb.24.313","article-title":"Assessment of gastric acidity of Japanese subjects over the Last 15 Years","volume":"24","author":"Morihara","year":"2001","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1381\/096089204322857690","article-title":"Pre- and postoperative esophageal and gastric pH levels in morbidly obese patients undergoing vertical gastroplasty","volume":"14","author":"Papavramidis","year":"2004","journal-title":"Obes. Surg."},{"key":"10.1016\/j.ejpb.2019.07.011_b0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/1471-2407-14-575","article-title":"Effect of gastrointestinal resection on sunitinib exposure in patients with GIST","volume":"14","author":"de Wit","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.2014.87","article-title":"pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development","volume":"96","author":"Zhang","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ejpb.2019.07.011_b0110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejpb.2019.07.011_b0115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-3495(98)74058-5","article-title":"The size of the unstirred layer as a function of the solute diffusion coefficient","volume":"75","author":"Pohl","year":"1998","journal-title":"Biophys. J."},{"issue":"5","key":"10.1016\/j.ejpb.2019.07.011_b0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jps.3030470522","article-title":"Investigation of drug release from solids II. Theoretical and experimental study of influences of bases and buffers on rates of dissolution of acidic solids","volume":"67","author":"Higuchi","year":"1958","journal-title":"J. Am. Pharm. Assoc."},{"issue":"7","key":"10.1016\/j.ejpb.2019.07.011_b0125","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2019.07.011_b0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2019.07.011_b0135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","article-title":"Model analysis of the concentration-dependent permeability of P-gp substrates","volume":"27","author":"Tachibana","year":"2010","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejpb.2019.07.011_b0140","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1023\/A:1025001131513","article-title":"Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium","volume":"20","author":"Troutman","year":"2003","journal-title":"Pharm. Res."},{"issue":"10\u201311","key":"10.1016\/j.ejpb.2019.07.011_b0145","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennern\u00e4s","year":"2007","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jps.2600740208","article-title":"Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts I: phenazopyridine","volume":"74","author":"Serajuddin","year":"1985","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2019.07.011_b0155","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","article-title":"Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test","volume":"23","author":"Takano","year":"2006","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0160","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.ejpb.2019.07.011_b0165","unstructured":"CDER, F. Highlights of Prescribing Information. CALQUENCE\u00ae (acalabrutinib) capsules, for oral use Initial U.S. Approval: 2017 2017 [cited 2017 12\/12\/2017]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf."},{"issue":"10","key":"10.1016\/j.ejpb.2019.07.011_b0170","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejpb.2019.07.011_b0175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","article-title":"Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test","volume":"22","author":"Lown","year":"1994","journal-title":"Drug Metab. Disposit.: Biol. Fate Chem."},{"issue":"3","key":"10.1016\/j.ejpb.2019.07.011_b0180","first-page":"217","article-title":"Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds","volume":"4","author":"Ho","year":"2001","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.07.011_b0185","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ejps.2016.09.037","article-title":"IMI - Oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 3: identifying gaps in system parameters by analysing In silico performance across different compound classes","volume":"96","author":"Darwich","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Pt A","key":"10.1016\/j.ejpb.2019.07.011_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.10.022","article-title":"Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies","volume":"220","author":"Koziolek","year":"2015","journal-title":"J. Contr. Rel."},{"key":"10.1016\/j.ejpb.2019.07.011_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2014.02.010","article-title":"In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation\/API\/excipient characterization including food effects","volume":"57","author":"Sjogren","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejpb.2019.07.011_b0200","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/nmo.12648","article-title":"On the validity of the (13) C-acetate breath test for comparing gastric emptying of different liquid test meals: a validation study using magnetic resonance imaging","volume":"27","author":"Bluemel","year":"2015","journal-title":"Neurogastroenterol. Motil.: Offic. J. Europ. Gastrointest. Motil. Soc."},{"issue":"2","key":"10.1016\/j.ejpb.2019.07.011_b0205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans: 4\u03b2-hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2019.07.011_b0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/jpm2040175","article-title":"The making of a CYP3A biomarker panel for guiding drug therapy","volume":"2","author":"Wang","year":"2012","journal-title":"J. Personal. Med."},{"key":"10.1016\/j.ejpb.2019.07.011_b0215","first-page":"3","article-title":"Evaluation of 4\u03b2-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a bayesian mechanism-based pharmacometric model","author":"Leil","year":"2014","journal-title":"CPT: Pharmacometr. Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2019.07.011_b0220","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12492","article-title":"Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral midazolam microdose phenotype in healthy subjects","volume":"118","author":"Woolsey","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejpb.2019.07.011_b0225","article-title":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input","author":"Pepin","year":"2019","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119303418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119303418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:39:21Z","timestamp":1760546361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119303418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":45,"alternative-id":["S0939641119303418"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.011","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}